These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 38396993)
1. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities. Ezzati S; Salib S; Balasubramaniam M; Aboud O Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993 [TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor as a therapeutic target in glioblastoma. Kalman B; Szep E; Garzuly F; Post DE Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987 [TBL] [Abstract][Full Text] [Related]
3. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825 [TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. An Z; Aksoy O; Zheng T; Fan QW; Weiss WA Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659 [TBL] [Abstract][Full Text] [Related]
5. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H Cells; 2019 Apr; 8(4):. PubMed ID: 31013819 [TBL] [Abstract][Full Text] [Related]
6. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. Roth P; Weller M Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii14-9. PubMed ID: 25342600 [TBL] [Abstract][Full Text] [Related]
7. Erlotinib in glioblastoma: lost in translation? Karpel-Massler G; Westhoff MA; Kast RE; Wirtz CR; Halatsch ME Anticancer Agents Med Chem; 2011 Oct; 11(8):748-55. PubMed ID: 21707495 [TBL] [Abstract][Full Text] [Related]
8. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. Westphal M; Maire CL; Lamszus K CNS Drugs; 2017 Sep; 31(9):723-735. PubMed ID: 28791656 [TBL] [Abstract][Full Text] [Related]
9. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231 [TBL] [Abstract][Full Text] [Related]
10. A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma. Kwatra MM Curr Cancer Drug Targets; 2017; 17(3):290-296. PubMed ID: 28029074 [TBL] [Abstract][Full Text] [Related]
18. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling. Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476 [TBL] [Abstract][Full Text] [Related]
19. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288 [TBL] [Abstract][Full Text] [Related]
20. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]